Uriprim

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uriprim

Quick Facts

Property Description
Active ingredient Allopurinol
Form Oral Tablets (Primary)
Pharmacological class Xanthine Oxidase Inhibitor
Common use Managing High Uric Acid Levels (Hyperuricemia)
Origin Synthetic Purine Analog

What Type of Medicine is Uriprim and What is its Purpose?

Uriprim is a prescription-only antihyperuricemic agent primarily utilized for the long-term management of high uric acid levels, a condition clinically recognized as hyperuricemia. The active chemical substance is Allopurinol, which places Uriprim within the Xanthine Oxidase Inhibitor pharmacological class. Allopurinol acts to reduce the amount of uric acid produced by the body, which is critical for stabilizing the body's chemistry and avoiding complications related to crystal formation.


Understanding Allopurinol: Composition and Form

The composition of Uriprim is centered on Allopurinol, a single-active-ingredient product synthesized as a purine analog. The drug is most frequently supplied as oral tablets, which constitutes the standard route of administration for achieving a consistent, daily therapeutic effect in chronic conditions. Uriprim is positioned as a brand-name drug containing the INN (International Nonproprietary Name), Allopurinol. Allopurinol and its primary metabolite, oxypurinol, inhibit the enzyme responsible for uric acid production, leading to decreased serum urate concentrations. This consistent composition provides a method for controlling serum urate concentrations over time.


The Chemical Action: How Uriprim Reduces Uric Acid

Uriprim acts as a "production blocker," interrupting the sequence that leads to the excessive creation of uric acid within the body. It achieves this effect by inhibiting the enzyme xanthine oxidase, which is essential in the purine catabolism process. This mechanism provides a systemic, foundational benefit: it lowers the total concentration of circulating uric acid. By slowing the key metabolic step, Uriprim directly controls the source of the chemical imbalance, offering a crucial measure for supporting long-term stability and health management.

Regulatory References

  1. NIH DailyMed drug label for ALLOPURINOL

What side effects are possible with Uriprim?

Possible Side Effects and Safety Information

The official safety information for Uriprim (Allopurinol) details possible adverse reactions and specific safety patterns based on frequency and affected body systems, as classified in regulatory documents.

Adverse Reaction Frequencies

Side effects are categorized based on their official incidence rates documented in prescribing information:

  • Common: Adverse reactions observed frequently include skin rash, which is the most reported effect.
  • Uncommon: Reactions classified as uncommon include general hypersensitivity reactions (specifically skin manifestations), nausea, vomiting, and elevated liver function tests (transaminases).
  • Rare: Documented rare adverse reactions include hepatitis, as well as severe cutaneous reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

System-Specific Safety Profile

Adverse reactions are grouped into System-Organ Classes (SOCs) in regulatory texts, highlighting effects on:

  • Skin and Subcutaneous Tissue: Focus is on rash and severe cutaneous adverse reactions (SCARs).
  • Hepatobiliary System: Includes abnormal liver function results and hepatitis.
  • Gastrointestinal System: Includes nausea, vomiting, and diarrhea.
  • Blood and Lymphatic System: Documented rare occurrences of severe cytopenias, such as aplastic anemia.

Serious and Contextual Safety Notes

Serious adverse reactions, though rare, are prominently featured, including SCARs and severe hematologic disorders. The official label notes that acute gout attacks are often more frequent at the start of treatment.

Population-Specific Safety: Regulatory documents explicitly mention increased risk of SCARs in patients of specific ethnic ancestries (e.g., Han Chinese, Thai, or Korean) associated with the *HLA-B5801 allele. Furthermore, safety monitoring is necessary for patients with impaired renal function** due to the drug's primary elimination pathway.

Overdose and Emergency Response

Overdose Manifestations and Emergency Action

Official regulatory documentation confirms that there is limited clinical experience with massive acute overdose of Uriprim (Allopurinol). In high-exposure cases, the documented clinical manifestations are primarily gastrointestinal disturbances, including Nausea, Vomiting, and Diarrhea.

When to Seek Immediate Medical Help

The regulatory profile strictly mandates that patients seek immediate emergency medical help for any sign of a Severe Cutaneous Adverse Reaction (SCAR). Uriprim must be discontinued immediately at the first appearance of a skin rash or symptoms of a systemic hypersensitivity reaction, such as fever or swollen glands, due to the risk of potentially fatal Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).

Serious outcomes also include the risk of acute renal failure due to xanthine crystalluria and potential hepatotoxicity. Patients with existing renal impairment face an elevated risk of severe toxicity because the drug and its metabolite are cleared primarily by the kidneys, necessitating close monitoring of both liver and renal function.

Management Protocol

Management is supportive and symptomatic. Regulatory sources state that no specific antidote is known to exist for Allopurinol overdose. Procedures such as Hemodialysis or Peritoneal Dialysis are described as procedural options for drug removal.

Therapeutic Uses of Uriprim

Main uses of Uriprim

Uriprim is a medication primarily indicated for the management of conditions associated with high levels of uric acid in the body. Its active ingredient, allopurinol, belongs to a class of drugs known as xanthine oxidase inhibitors. By reducing the production of uric acid, Uriprim helps address several metabolic and inflammatory issues.

Treatment of Gout

The primary use of Uriprim is the long-term management of gout. Gout is a form of inflammatory arthritis caused by the accumulation of urate crystals in the joints. By lowering serum uric acid levels, the medication prevents the formation of new crystals and allows existing deposits to gradually dissolve. This process helps reduce the frequency and severity of gout attacks and prevents chronic joint damage.

Management of Kidney Stones

Uriprim is utilized in patients who suffer from recurrent calcium oxalate kidney stones when there is an associated high level of uric acid in the urine (hyperuricosuria). Additionally, it is used to prevent the formation of uric acid stones, which can occur when the urine becomes too saturated with the substance.

Hyperuricemia Related to Medical Therapies

Certain medical treatments, particularly chemotherapy or radiation therapy for leukemia, lymphoma, and other malignancies, can cause a rapid breakdown of cells. This process often leads to a significant increase in uric acid levels (secondary hyperuricemia). Uriprim is administered in these clinical settings to manage these levels and protect kidney function.

Benefits of Treatment

Prevention of Tissue Damage

By maintaining uric acid within a physiological range, Uriprim helps prevent the formation of tophi—hardened deposits of uric acid under the skin or around joints. This reduction in crystal buildup is essential for maintaining joint mobility and preventing permanent structural changes.

Renal Protection

Excessive uric acid can lead to kidney dysfunction or the development of interstitial nephritis. By controlling the systemic production of uric acid, Uriprim assists in lowering the metabolic burden on the kidneys, thereby reducing the risk of urate-related renal complications.

Stability of Uric Acid Levels

The consistent use of the medication facilitates a stable metabolic environment. Rather than treating acute inflammation, the benefit of Uriprim lies in its ability to address the underlying biochemical cause of hyperuricemia, leading to better long-term outcomes for patients with metabolic predispositions to high uric acid.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Uriprim?

The official regulatory labeling for Uriprim (Allopurinol) defines strict population eligibility rules based on risk profiles, age, and underlying health conditions.

Absolute Non-Eligibility (Contraindications)

Category Restriction
Hypersensitivity Contraindicated in patients with a history of severe reactions (including SJS, TEN, or DRESS) to Allopurinol.

Restricted and Conditional Use

Population Group Regulatory Status
Organ Impairment Patients with impaired renal or hepatic function must receive reduced doses.
Genetic Risk Use is not recommended in specific ethnic populations carrying the *HLA-B58:01 allele**.
Age Groups Use in children is contraindicated except for specific conditions like malignancy-related hyperuricemia. Older adults require cautious dose selection based on renal function.
Pregnancy Should not be used unless considered medically essential.
Asymptomatic Condition Use is not indicated for elevated uric acid levels without clinical symptoms (asymptomatic hyperuricemia).

The eligibility profile is defined by regulatory documents that mandate specific cautions and exclusions, ensuring the medicine is used only by approved populations under defined circumstances.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Uriprim (Allopurinol) has officially documented interaction patterns that are primarily defined by its effect on xanthine metabolism and drug clearance, as stated in regulatory labels. Co-administration of Pegloticase is a formally contraindicated combination and Allopurinol therapy must be discontinued.

The regulatory profile mandates significant caution and dosage adjustments for several medicines, particularly those affected by the inhibition of Xanthine Oxidase.

Interacting Medicine Official Regulatory Outcome
Mercaptopurine, Azathioprine Allopurinol inhibits metabolic inactivation, leading to substantially increased plasma concentrations and toxicity risk.
Didanosine Plasma exposure ( C max and AUC) is approximately doubled; co-administration is generally not recommended.
Thiazide Diuretics Increased risk of severe hypersensitivity reactions, particularly in patients with chronic renal impairment.
Uricosuric Agents (e.g., Probenecid) May accelerate the excretion of the active metabolite, oxipurinol, potentially decreasing the efficacy of Allopurinol.
Aluminum Hydroxide Requires a 3-hour separation of administration to prevent a decrease in Allopurinol's therapeutic efficacy.

Other agents, including Theophylline, Cyclosporin, and Coumarin Anticoagulants (e.g., Warfarin), have also been documented to have increased plasma concentrations or effects when co-administered with Allopurinol, requiring regulatory-aligned monitoring.

Mechanism of Action

Uriprim's action is defined by a highly specific, dual-component strategy aimed at controlling the synthesis of uric acid. The full mechanism operates through direct enzyme inhibition, leading to a significant alteration in the purine catabolism pathway.


Chemical Blockade of Uric Acid Synthesis

The active compound, Allopurinol, is quickly converted to its primary metabolite, Oxypurinol. Both compounds act as inhibitors of the Xanthine Oxidase (XO) enzyme, which catalyzes the final metabolic step of purine breakdown. This highly specific chemical blockade limits the formation of uric acid, initiating the key mechanistic cascade.


Altering Purine Metabolite Homeostasis

By inhibiting Xanthine Oxidase, Uriprim forces the accumulation of the purine precursors, Hypoxanthine and Xanthine, upstream of the blocked step. These precursor molecules are significantly more water-soluble than uric acid, allowing the precursors to be readily excreted via the kidneys due to their high water solubility. This shift in the ratio of metabolites leads to a sustained reduction in the overall systemic concentration of serum urate, which is the primary physiological consequence of the drug's action.

Dosage and Administration Information

How to Use Uriprim

Uriprim (allopurinol) is administered primarily as oral tablets for the sustained, chronic management of hyperuricemia. The medicine is also available as a powder for injection for intravenous (IV) administration, which is typically used when the oral route is not feasible or for prophylaxis in specific acute conditions.

The standard oral protocol requires a stepwise titration to establish the correct dose. Treatment is initiated at a low daily amount, such as 100 mg, which is then gradually increased in increments (e.g., 100 mg per week) until the required therapeutic concentration is reached. The typical adult maintenance range is between 200 mg and 600 mg daily, with a maximum limit of 800 mg per day.

Dosing frequency is dependent on the total daily amount. While lower doses are taken once daily, any total daily dose exceeding 300 mg must be administered in divided portions to minimize gastrointestinal upset. Tablets are to be taken after a meal. An explicit procedural requirement is the maintenance of a high fluid intake to promote urinary output of at least two liters daily.

Dose modifications are required for specific patient groups. Patients with impaired renal function must be started on a significantly lower initial dose, and dosing frequency may be reduced according to the degree of kidney impairment. Pediatric dosing is determined by body weight, with a typical maximum of 400 mg daily. If a daily dose is missed, instructions are not to take a double dose to make up for the omission.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uriprim (Allopurinol)


Evidence for Managing Chronic High Uric Acid Levels and Gout Symptoms

For the long-term management of gout, research has been conducted primarily using study types such as Randomized Controlled Trials (RCTs) and comprehensive reviews of these trials, known as meta-analyses. These studies focused on adults with established gout and existing findings of high levels of uric acid in their blood (hyperuricemia). Researchers monitored how low the serum urate (SU) levels became, whether participants reached pre-defined target SU concentrations, and whether the frequency of gout flares changed.

Findings describe patterns observed in the studies related to the changes in serum urate levels and the incidence and frequency of acute gout episodes. Studies also monitored the assessment of urate deposits (tophi) shrinking. A limitation is the noted variability (heterogeneity) across existing trials regarding treatment dosages. Furthermore, long-term stability of the observed changes in flare frequency is less characterized beyond intermediate follow-up periods.


Research on Preventing Hyperuricemia During Cancer Treatment

Uriprim was evaluated in Comparative RCTs and retrospective analyses to explore its role in managing the acute increase in uric acid levels that can occur after some chemotherapy treatments (Tumor Lysis Syndrome or TLS). Studies were conducted in both adult and pediatric patients at risk for this complication. Research monitored the control and changes in Plasma Uric Acid (PUA) levels over a short, acute period of about three to seven days.

Reported patterns were used to gauge the outcomes related to preventing the signs of laboratory and clinical TLS. Studies reported that the timeframe to observe changes in PUA levels was monitored in comparison to other therapeutic approaches. The research is characterized by a short follow-up duration, aligning only with the immediate, acute risk period.


Research on Managing Recurrent Kidney Stone Formation

The research foundation includes Randomized, Double-Blind, Placebo-Controlled Trials that tracked adults with a history of recurrent calcium oxalate kidney stones, specifically those with existing findings of hyperuricosuria (excess uric acid in the urine). The trials examined outcomes by tracking the annual recurrence rate of stone events per patient over several years.

Studies reported measurements of the rate of stone recurrence. Evidence is limited in that the biological process explaining how the uric acid modification affects the formation of calcium-based stones is an area of continued scientific exploration. The long-term recurrence data is derived from studies with a finite follow-up period.

Frequently Asked Questions (FAQ)

Common questions about Uriprim (FAQ)

Q: How quickly does Uriprim usually start to work?

Studies and official information indicate that a reduction in the body's uric acid levels can often be measured within 24 to 48 hours of starting Uriprim. However, for the full, long-term therapeutic effect to stabilize uric acid levels for chronic management, it may take a few weeks of consistent use. This pattern aligns with the medicine's role in the sustained management of chronic conditions.

Q: Does Uriprim cause drowsiness or affect driving?

Regulatory documents state that side effects like dizziness and drowsiness (somnolence) have been reported in official product information. Should these effects occur, regulatory documents indicate the need for caution regarding activities like driving or operating machinery.

Q: Is Uriprim known to interact with caffeine?

While official regulatory labels do not typically list caffeine as a specific interaction, Uriprim is known to affect the metabolism of other xanthine-derived substances, such as Theophylline, by inhibiting a specific enzyme. This is why official warnings advise that caution may be necessary regarding the metabolism of similar compounds.

Q: Are there certain foods or drinks to avoid while using Uriprim?

Official administration instructions describe maintaining a high fluid intake, often noted as at least two liters daily, to promote adequate urinary output. Regulatory warnings also advise that alcohol consumption may worsen the underlying condition or potentially increase the risk of certain side effects like drowsiness.

Q: How long after starting Uriprim might side effects appear?

Official product information notes that acute gout attacks may be more frequent during the initial period of treatment. Other common side effects, such as a mild rash or stomach upset, may appear shortly after beginning use. However, rare but serious skin reactions may not occur until weeks or even months after starting the medicine.

Q: Does Uriprim have any known interactions with common supplements like vitamin C?

Vitamin C (ascorbic acid) is not typically listed as a formal drug interaction in core regulatory tables. However, large amounts of Vitamin C may potentially influence urate metabolism by changing the acidity of the urine. Official guidance emphasizes the importance of reviewing the use of all supplements with a healthcare provider.

Q: Does Uriprim affect blood pressure?

Blood pressure changes, including high blood pressure (hypertension) or chest pain, have been reported very rarely as possible side effects in some regulatory summaries. Some research has also been conducted to explore a possible positive effect on blood pressure in specific patient groups.

Q: Can Uriprim cause changes in mood or anxiety?

Official product information lists rare or very rare adverse reactions affecting the nervous system and mood. These reported effects include symptoms such as depression, confusion, and agitation.

Q: Is Uriprim safe to use with standard painkillers like ibuprofen?

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which include common painkillers like ibuprofen, are frequently used alongside Uriprim for acute symptoms. While the core regulatory interaction profile does not usually list a direct interaction with ibuprofen, official labels still advise monitoring when these medicines are used together.

Q: Can Uriprim cause dry mouth?

Dry mouth is specifically noted as a possible side effect in the official regulatory documentation for this medicine, typically categorized in the rare or very rare frequency groups.

Q: How should Uriprim be stopped once the course is finished?

Uriprim is generally intended for the long-term management of chronic conditions, so official guidance emphasizes that discontinuation is typically managed following a medical review. Regulatory guidance also notes that close monitoring of uric acid levels may be emphasized when considering stopping the use of the medicine.

Q: Is it common to feel tired while taking Uriprim?

While not always classified as a common effect, general feelings of being unwell, weak, or tired have been reported in the regulatory documents, typically within the uncommon or rare frequency categories.

Q: Does Uriprim interact with alcohol?

Official regulatory guidance often states that alcohol consumption may worsen the underlying condition Uriprim is treating. Additionally, alcohol may increase the risk of certain side effects caused by Uriprim, such as drowsiness or other nervous system effects.

Q: How long does Uriprim stay in the body after the last use?

According to the medicine's pharmacokinetics section in official documents, the active substance itself has a short half-life of about 1.2 hours. However, the primary active metabolite, which provides most of the therapeutic effect, stays in the body longer, with a half-life of approximately 18 to 30 hours in individuals with normal kidney function.

Q: Is Uriprim associated with headaches?

Headache is listed as a possible side effect in the official regulatory documentation for this medicine.

Q: Can I take Uriprim if I am already on an antibiotic?

Regulatory documents list certain antibiotics, specifically Amoxicillin and Ampicillin, as potentially increasing the risk of developing a skin rash when used concurrently with Uriprim. For other types of antibiotics, official guidance advises checking the drug interaction guide.

Q: Can I use Uriprim if I am breastfeeding?

Official product information generally recommends avoiding the medicine during breastfeeding. This is because both the drug and its active metabolite are known to pass into breast milk, and the manufacturer notes that caution or avoidance is generally indicated unless the benefit is medically essential.

Q: Is Uriprim associated with any specific vision problems?

Regulatory documents list potential side effects affecting vision, including visual disturbances and blurred vision. Cataracts have been reported rarely, especially with long-term use of the medicine.

How should Uriprim be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal instructions for Allopurinol (the active substance in Uriprim) are strictly defined by regulatory authorities to ensure product stability and safety.

Storage Conditions:

Requirement Specific Instruction
Temperature Do not store above 25 C.
Protection Store blister strips in the original package.
Handling Keep tablet containers tightly closed and in the original container.

Product Stability:

Packaging Type Shelf-Life
Tablet containers 3 years
Blister strips 2 years

Disposal instructions state no special requirements are listed in official documentation; therefore, expired or unused medicine should be discarded according to local established pharmaceutical disposal policies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uriprim found in:

A-Z Index: